Cerevance's solengepras failed to meet its primary endpoint in the ASCEND trial, which sought to evaluate it as a monotherapy ...

IoT helps to decentralise clinical trials while providing pharmaceutical companies with a higher return on investment.

At the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD), Roche announced topline results ...

Higher doses of the company’s multiple sclerosis drug failed to show additional benefit in slowing rates of disability ...

Antag Therapeutics has commenced a first-in-human, double-blind Phase Ia trial of the GIPR antagonist, AT-7687, intended for ...

BioMarin has reported that the multi-centre Phase III PEGASUS trial of Palynziq (pegvaliase-pqpz) has met its primary ...

AC Immune has reported additional interim safety and positive immunogenicity outcomes from its placebo-controlled Phase II VacSYn trial.